Clinical trials: Compensated Advanced Chronic Liver Disease
Advanced Chronic Liver Disease, Portal Hypertension
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Zinc homeostasis could play a role in advanced chronic liver disease (cACLD) and its supplementation has been linked with improvement in liver function, decrease of hepatic complications and reduction in hepatocellular carcinoma…
- Conditions
- Advanced Chronic Liver Disease, Portal Hypertension, Hepatocellular Carcinoma
- Trial name
- NCT06434753
- Testing
- Zinc Acexamate
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Compensated Advanced Chronic Liver Disease, Variceal Hemorrhage
Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004)
Variceal hemorrhage is the serious complication in patients with compensated advanced chronic liver disease (cACLD). To evaluate the bleeding risk of varices, esophagogastroduodenoscopy (EGD) should be performed.
- Trial name
- NCT04546360
- Testing
- Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.
- Where
- 6 sites in China
- Volunteers
- 381 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Compensated Advanced Chronic Liver Disease, Varices Needing Treatment
CHESS Criteria for Varices Screening in Compensated Advanced Chronic Liver Disease (CHESS2001/APPHA2001)
Variceal hemorrhage is the serious complication in patients with compensated advanced chronic liver disease (cACLD). To evaluate the bleeding risk of varices in cACLD, esophagogastroduodenoscopy (EGD) should be performed.
- Trial name
- NCT04307264
- Testing
- Esophagogasrtoduodendoscopy, liver stiffness measurement
- Where
- 15 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
MAFLD
Liver Stiffness Changes by iLivTouch to Predict Liver-Related Events in MAFLD
This is an observational study (multicenter retrospective real-world cohort study). The purpose of this study is to assess the predictive performance of liver stiffness measurement (LSM, including baseline LSM1, current LSMC and…
- Trial name
- MAFLD (NCT07777198)
- Volunteers
- 2,303 people
- Sponsor
- Beijing Friendship Hospital